Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment

被引:54
作者
Wang, Chi-Pin James [1 ,2 ]
Byun, Min Ji [1 ,2 ]
Kim, Se-Na [3 ]
Park, Wooram [4 ]
Park, Hee Ho [5 ]
Kim, Tae-Hyung [6 ]
Lee, Jung Seung [1 ,2 ]
Park, Chun Gwon [1 ,2 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Biomed Engn, Suwon 16419, Gyeonggi, South Korea
[2] Sungkyunkwan Univ, Dept Intelligent Precis Healthcare Convergence, Suwon, South Korea
[3] Seoul Natl Univ, Inst Med & Biol Engn, Med Res Ctr, Seoul 03080, South Korea
[4] Sungkyunkwan Univ SKKU, Coll Biotechnol & Bioengn, Dept Integrat Biotechnol, Suwon 16419, Gyeonggi, South Korea
[5] Hanyang Univ, Dept Bioengn, Seoul 04763, South Korea
[6] Chung Ang Univ, Sch Integrat Engn, 84 Heukseok Ro, Seoul 06974, South Korea
[7] Sungkyunkwan Univ, Biomed Inst Convergence SKKU BICS, Suwon 16419, Gyeonggi, South Korea
[8] Inst Basic Sci IBS, Ctr Neurosci Imaging Res, Suwon 16419, Gyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
Inflammatory bowel disease; Drug-delivery system; Biomaterials; Nanoparticle; microparticle; Hydrogel; SOLID LIPID NANOPARTICLES; MOLECULAR-WEIGHT HEPARIN; MESENCHYMAL STEM-CELLS; ULCERATIVE-COLITIS; PLATINUM NANOPARTICLES; CROHNS-DISEASE; ORAL DELIVERY; ANTIINFLAMMATORY PROPERTIES; CHITOSAN NANOPARTICLES; SURFACE MODIFICATION;
D O I
10.1016/j.jconrel.2022.02.028
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such as corticosteroids, antibiotics, and immunosuppressants has been proven. However, the delivery of free drugs is insufficient and inadequate since some patients have experienced reduced efficacy due to repeated administration and others have suffered side effects. In this regard, novel platforms based on biomaterials are required to deliver pharmaceutical agents to the damaged site with increased efficacy and reduced side effects. In this review, we summarize the most recent status of numerous biomaterials in treating IBD. This review addresses various nanoparticles, microparticles, and hydrogels recently prepared from natural polymers, lipids, synthetic polymers, and inorganic materials. These diverse biomaterials can be used as effective drug-delivery systems to promote colon-specific delivery and for the stable release of drugs in IBD treatments.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 165 条
[1]   Novel biodegradable pH-sensitive hydrogels: An efficient controlled release system to manage ulcerative colitis [J].
Abbasi, Mudassir ;
Sohail, Muhammad ;
Minhas, Muhammad Usman ;
Khan, Shahzeb ;
Hussain, Zahid ;
Mahmood, Arshad ;
Shah, Syed Ahmed ;
Kousar, Mubeen .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 136 :83-96
[2]   Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression [J].
Abdelmegid, Amira M. ;
Abdo, Fadia K. ;
Ahmed, Fayza E. ;
Kattaia, Asmaa A. A. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[3]   Aminocellulose-grafted polycaprolactone-coated core-shell nanoparticles alleviate the severity of ulcerative colitis: a novel adjuvant therapeutic approach [J].
Ahmad, Anas ;
Ansari, Md Meraj ;
Kumar, Ajay ;
Bishnoi, Mahendra ;
Raza, Syed Shadab ;
Khan, Rehan .
BIOMATERIALS SCIENCE, 2021, 9 (17) :5868-5883
[4]   The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review [J].
Aldars-Garcia, Laila ;
Marin, Alicia C. ;
Chaparro, Maria ;
Gisbert, Javier P. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) :1-15
[5]   Nanoceria as a possible agent for the management of COVID-19 [J].
Allawadhi, Prince ;
Khurana, Amit ;
Allwadhi, Sachin ;
Joshi, Kamaldeep ;
Packirisamy, Gopinath ;
Bharani, Kala Kumar .
NANO TODAY, 2020, 35
[6]   Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota [J].
Altajar S. ;
Moss A. .
Current Gastroenterology Reports, 2020, 22 (12)
[7]   Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study [J].
Ananthakrishnan, Ashwin N. ;
Khalili, Hamed ;
Konijeti, Gauree G. ;
Higuchi, Leslie M. ;
de Silva, Punyanganie ;
Fuchs, Charles S. ;
Richter, James M. ;
Schernhammer, Eva S. ;
Chan, Andrew T. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (11) :1879-1886
[8]   Sleep Disturbance and Risk of Active Disease in Patients With Crohn's Disease and Ulcerative Colitis [J].
Ananthakrishnan, Ashwin N. ;
Long, Millie D. ;
Martin, Christopher F. ;
Sandler, Robert S. ;
Kappelman, Michael D. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (08) :965-971
[9]   A Review of Clinical Translation of Inorganic Nanoparticles [J].
Anselmo, Aaron C. ;
Mitragotri, Samir .
AAPS JOURNAL, 2015, 17 (05) :1041-1054
[10]   Eluxadoline Loaded Solid Lipid Nanoparticles for Improved Colon Targeting in Rat Model of Ulcerative Colitis [J].
Anwer, Md. Khalid ;
Ahmed, Mohammed Muqtader ;
Aldawsari, Mohammed F. ;
Alshahrani, Saad ;
Fatima, Farhat ;
Ansari, Mohd Nazam ;
Rehman, Najeeb Ur ;
Al-Shdefat, Ramadan I. .
PHARMACEUTICALS, 2020, 13 (09) :1-16